目的 探討采用少腹逐瘀顆粒聯(lián)合屈螺酮炔雌醇治療子宮內(nèi)膜異位癥的臨床療效。方法 選取中山醫(yī)院青浦分院2015年3月-2016年3月收治的子宮內(nèi)膜異位癥患者121例，隨機(jī)分成對照組（60例）和治療組（61例）。對照組患者口服屈螺酮炔雌醇片，1片/次，1次/d，月經(jīng)來潮后第5天服用，連續(xù)使用至下次月經(jīng)來潮為1個周期；治療組患者在對照組基礎(chǔ)上口服少腹逐瘀顆粒，0.6 g/次，2次/d。兩組患者連續(xù)治療3個月經(jīng)周期。評價兩組患者臨床療效，同時比較治療前后兩組患者CA125水平、痛經(jīng)評分、盆腔包塊體積、痛覺、生育能力、復(fù)發(fā)率和不良反應(yīng)。結(jié)果 治療后，對照組的臨床總有效率為81.67%，顯著低于治療組患者的96.72%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者CA125水平、痛經(jīng)評分和盆腔包塊直徑均明顯降低（P<0.05）；且治療后治療組患者的CA125水平、痛經(jīng)評分和盆腔包塊直徑比對照組降低的更明顯（P<0.05）。隨訪1年發(fā)現(xiàn)，治療組患者復(fù)發(fā)率明顯低于對照組（P<0.05），且治療組生育能力明顯強(qiáng)于對照組（P<0.05），痛覺人數(shù)明顯少于對照組（P<0.05）。治療期間，對照組患者的不良反應(yīng)發(fā)生率為21.67%，明顯高于治療組患者的6.56%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 少腹逐瘀顆粒聯(lián)合屈螺酮炔雌醇治療子宮內(nèi)膜異位癥療效顯著，安全性高，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical efficacy of Shaofu Zhuyu Granules combined with drospirenone and ethinylestradiol in treatment of endometriosis. Methods Patients (121 cases) with endometriosis in Qingpu Branch of Zhongshan Hospital from March 2015 to March 2016 were randomly divided into control (60 cases) and treatment (61 cases) groups. Patients in the control group were po administered with Drospirenone and Ethinylestradiol Tablets after the fifth days of menstruation until the next menstruation, 1 tablet/time, once daily. Patients in the treatment group were po administered with Shaofu Zhuyu Granules on the basis of the control group, 0.6 g/time, twice daily. Patients in two groups were treated for three menstrual periods. After treatment, the clinical efficacy was evaluated, and the CA125 levels, dysmenorrhea scores, and pelvic mass volume, pain, potentia generandi, recurrence rates, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.67%, which was significantly lower than 96.72% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the CA125 level, dysmenorrhea scores, and pelvic mass volume were significantly decreased (P<0.05). And these indicators in the treatment group decreased more significantly than those in the control group (P<0.05). Follow up for 1 year showed that recurrence rate in the treatment group was significantly lower than that in the control group (P<0.05), and the potentia generandi of the treatment group was significantly stronger than that of the control group (P<0.05), the patients of pain were significantly less than those in the control group (P<0.05). During the treatment, the adverse reaction rate in the control group was 21.67%, which was significantly higher than 6.56% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Shaofu Zhuyu Granules combined with drospirenone and ethinylestradiol has a significant effect in treatment of endometriosis with high safety, which has a certain clinical application value.